""I want to emphasize that this transfer of veltuzumab back to us is not due to a lack of efficacy or safety of the antibody but a lack of progress with its development," commented Cynthia L. Sullivan, President and Chief Executive Officer of Immunomedics. "We have begun the process of evaluating our options for this important antibody," Ms. Sullivan added. "
Just curious, how much this treatment worth if approved?
I think someone else has a major interest in Veltuzumab....Sounds like the President/ CEO has been working hard to make sure this agreement got terminated....It is my belief they already have something lined up!!!...stay tuned, this could get interesting!!!